Newsroom

Featured

Alvotech completes enrollment of phase III study involving biosimilar version of Humira®

  • Alvotech AVT02 is developed as a high concentration (100mg/mL) formulation, expected to be more convenient for patients, differentiating from most biosimilar competitors
  • 407 participants enrolled in the Phase III study, at approximately 30 sites across Europe
  • Simultaneous Phase I PK comparability study is ongoing
  • Alvotech is also conducting related autoinjector clinical studies

Read More
MEET THE MANAGEMENT

Highly experienced management team with a proven track record of achieving high...

Media Gallery

Download center for company logos and images.

News alert

Enter your email to sign up for news alerts

MEDIA CONTACT

Halldor Kristmannsson 
Vice President
Organizational Development
Global Communications & Branding

Phone (354) 522-2900

Email
Connect on LinkedIn

We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. Learn more.